Mark J Goulet

US Patent:

7012084, Mar 14, 2006

Filed:

Feb 25, 2002

Appl. No.:

10/468517

Inventors:

Mark T. Goulet - Lexington MA, US
Ravi P. Nargund - East Brunswick NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Thomas F. Walsh - Watchung NJ, US
Daniel Warner - Stoneham MA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/445
C07D 211/06

US Classification:

514330, 514317, 514323, 546208, 546212, 546224, 546226

Abstract:

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

US Patent:

7622449, Nov 24, 2009

Filed:

Jun 15, 2005

Appl. No.:

11/153192

Inventors:

Mark T. Goulet - Lexington MA, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Anthony Ogawa - Mountainside NJ, US
Derek Von Langen - Scotch Plains NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 15/203
C07H 15/26
A61P 9/10
A61P 3/06
A61K 31/7052
C07D 205/08
A61K 31/397

US Classification:

514 25, 536 174, 540200, 514 32

Abstract:

This invention provides cholesterol absorption inhibitors of Formula I:.

US Patent:

20090048276, Feb 19, 2009

Filed:

Jan 26, 2007

Appl. No.:

12/223305

Inventors:

Mark T. Goulet - Lexington MA, US
Benito Munoz - Brookline MA, US
Alexey A. Rivkin - Boston MA, US

International Classification:

A61K 31/519
C07D 215/20
C07D 471/04
C07D 491/04
C07D 471/12
C07D 471/14
A61P 3/06
A61P 35/00
A61K 31/4412
C07D 213/69
A61K 31/47
A61K 31/438
A61K 31/436

US Classification:

5142641, 546157, 546119, 546 92, 546 86, 546116, 544279, 544251, 546296, 514312, 514300, 514302, 514267, 514348

Abstract:

The instant invention provides for compounds which comprise substituted 3-aryl-4-hydroxyquinolin-2(1H)-ones that inhibit FAS activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting FAS activity by administering the compound to a patient in need of treatment of cancer.